Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection

• Published in: United European gastroenterology journal Vol. 5; no. 6; pp. 868 - 879
• Main Authors: van Beurden, Yvette H, de Groot, Pieter F, van Nood, Els, Nieuwdorp, Max, Keller, Josbert J, Goorhuis, Abraham
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.10.2017
• Subjects: Clostridium difficile; complications; fecal microbiota transplantation (FMT); infection (CDI); long‐term follow‐up; nasoduodenal tube; Original; infection (CDI); nasoduodenal tube; complications; fecal microbiota transplantation (FMT); long-term follow-up; Clostridium difficile
• ISSN: 2050-6406; 2050-6414
• DOI: 10.1177/2050640616678099

Background Fecal microbiota transfer (FMT) is an effective treatment for recurrent Clostridium difficile infection (CDI), but data on procedure-related complications and long-term outcome are scarce. Methods All patients treated with FMT for recurrent CDI at the Academic Medical Center between July 2010 and January 2016 were included. FMT was performed according to the FECAL trial protocol: administration of fresh donor feces (related or unrelated donor) through a duodenal tube after pre-treatment with vancomycin and bowel lavage. We collected information on FMT-related complications, recurrent CDI, and short- and long-term adverse events by telephone interviews using a structured questionnaire at three months after FMT, and at the time of data collection of this study. Results In total, 39 patients were treated with FMT. The primary cure rate (no recurrence ≤8 weeks after one infusion with donor feces) was 82% (32 of 39 patients). Of the seven patients with recurrent CDI after FMT, four were cured by antibiotic therapy alone (fidaxomicin in three patients, metronidazole in one patient) and three by repeat FMT. Peri-procedural complications occurred in five patients, comprising fecal regurgitation or vomiting. One patient died one week post-FMT due to pneumonia; a causal relation with FMT could not be excluded. The follow-up period ranged between 3 and 68 months. No long-term side effects were reported. Conclusions Our data underline the efficacy of FMT as treatment for recurrent CDI. Importantly, it is possible to cure post-FMT recurrences with antibiotic therapy alone. Peri-procedural complications do occur and should be closely monitored to help identify high-risk patients. To minimize the risk of complications, all FMT candidates should be evaluated to assess the most ideal delivery method.